← Search & browse all drugs

samarium (153Sm) hydroxyapatite colloid

V10AX02

Forms & Strengths

Injectable suspension: 1.85 GBq/mL (50 mCi/mL) at calibration time
Radioactive diagnostic/therapeutic agent supplied in single-dose glass vials

Adult Dosing

Palliative treatment of bone pain: 37 MBq/kg (1.0 mCi/kg) body weight administered via slow intravenous injection over 1 minute

Pediatric Dosing

Safety and efficacy in pediatric patients below the age of 18 years have not been established

Indications

Palliative treatment of bone pain in patients with osteoblastic bone metastases

Mechanism of Action

Beta-emitting radioisotope that localizes in areas of active osteoblastic bone formation, delivering targeted ionizing radiation to relieve metastatic bone pain

Contraindications

Hypersensitivity to samarium or phosphonate compounds
Pregnancy and lactation
Severe bone marrow suppression unless deemed medically necessary

Adverse Reactions

Transient myelosuppression (leukopenia and thrombocytopenia)
Nausea and vomiting
Pain flare shortly after administration
Injection site reactions

Drug Interactions

Calcitonin or other bone metabolism modifiers may theoretically alter uptake of samarium 153Sm hydroxyapatite
Concurrent chemotherapy or external beam radiation therapy increases the risk of severe bone marrow suppression

Curated Content: Needs Vetting Before Put to Clinical Use